Sanofi India Limited
NSE: SANOFI BSE: SANOFI
Prev Close
4372.8
Open Price
4372.8
Volume
17,076
Today Low / High
4305 / 4378
52 WK Low / High
4305 / 6717
Range
4,120 - 4,554
Prev Close
4371.7
Open Price
4371.7
Volume
38,919
Today Low / High
4301 / 4379.9
52 WK Low / High
4145.9 / 6717.5
Range
4,118 - 4,551
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 4337.3 (target range: 4,120 - 4,554), reflecting a change of -35.5 (-0.81184%). On the BSE, it is listed at 4334.4 (target range: 4,118 - 4,551), showing a change of -37.3 (-0.85321%). The stock price is currently in decline on both exchanges, signaling a downtrend. If you're considering investing in this stock, it's important to monitor the situation closely.
Sanofi India Limited Graph
Sanofi India Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Sanofi India Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 4,337.30, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 4,334.40 | 4,377.74 | 3,939.97 - 4,815.52 |
| 4,421.09 | 3,536.87 - 5,305.31 | ||
| 4,464.43 | 3,125.10 - 5,803.76 | ||
| Bearish Scenario | 4,334.40 | 4,291.06 | 3,861.95 - 4,720.16 |
| 4,247.71 | 3,398.17 - 5,097.25 | ||
| 4,204.37 | 2,943.06 - 5,465.68 |
Overview of Sanofi India Limited
ISIN
INE058A01010
Industry
Drug Manufacturers - General
Vol.Avg
16,299
Market Cap
99,890,716,801
Last Dividend
192
Official Website
IPO Date
2002-07-01
DCF Diff
-976.84
DCF
5,307
Financial Ratios Every Investor Needs
Stock Dividend of SANOFI
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2025-11-07 | November 07, 25 | 75 | 75 | 2025-11-07 | 2025-11-28 | |
| 2025-04-25 | April 25, 25 | 117 | 117 | 2025-04-25 | 2025-06-14 | |
| 2024-05-03 | May 03, 24 | 117 | 117 | 2024-05-03 | 2024-05-24 | |
| 2024-03-07 | March 07, 24 | 50 | 50 | 2024-03-07 | 2024-03-20 | |
| 2023-04-28 | April 28, 23 | 183 | 183 | 2023-04-28 | 2023-06-10 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | 2,013.20 Cr | 994.20 Cr | 1,019.00 Cr | 0.5062 | 1.10 Cr | 241.90 Cr | 758.10 Cr | 413.30 Cr | 136.21 | 485.20 Cr | 0.2053 |
| 2023-12-31 | 1,996.10 Cr | 965.10 Cr | 1,031.00 Cr | 0.5165 | 0.60 Cr | 281.40 Cr | 725.40 Cr | 602.90 Cr | 158.31 | 484.70 Cr | 0.3020 |
| 2022-12-31 | 2,770.10 Cr | 1,205.30 Cr | 1,564.80 Cr | 0.5649 | 0.20 Cr | 407.60 Cr | 1,123.20 Cr | 620.60 Cr | 269.47 | 698.40 Cr | 0.2240 |
| 2021-12-31 | 2,956.60 Cr | 1,323.50 Cr | 1,633.10 Cr | 0.5524 | 0.40 Cr | 437.50 Cr | 1,149.10 Cr | 944.40 Cr | 410.06 | 753.70 Cr | 0.3194 |
| 2020-12-31 | 2,901.90 Cr | 1,279.00 Cr | 1,622.90 Cr | 0.5593 | 0.30 Cr | 466.20 Cr | 1,106.20 Cr | 477.60 Cr | 207.38 | 709.10 Cr | 0.1646 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | 283.80 Cr | 1,611.80 Cr | 751.20 Cr | 860.6000 Cr | 19.30 Cr | -264.50 Cr | 499.80 Cr | 329.30 Cr | 0.00 Cr | 0.00 Cr | -43.50 Cr | 719.2000 Cr |
| 2023-12-31 | 394.50 Cr | 1,714.80 Cr | 699.60 Cr | 1,015.2000 Cr | 19.00 Cr | -375.50 Cr | 663.80 Cr | 323.30 Cr | 0.00 Cr | 0.00 Cr | 4.40 Cr | 651.3000 Cr |
| 2022-12-31 | 1,004.90 Cr | 2,071.70 Cr | 795.90 Cr | 1,275.8000 Cr | 23.60 Cr | -981.30 Cr | 408.00 Cr | 324.00 Cr | 4.70 Cr | 0.00 Cr | -4.30 Cr | 740.6000 Cr |
| 2021-12-31 | 1,538.00 Cr | 3,061.00 Cr | 835.40 Cr | 2,225.6000 Cr | 24.60 Cr | -1,513.40 Cr | 392.40 Cr | 341.70 Cr | 356.50 Cr | 0.00 Cr | -9.10 Cr | 749.6000 Cr |
| 2020-12-31 | 1,197.40 Cr | 2,918.50 Cr | 799.50 Cr | 2,119.0000 Cr | 22.60 Cr | -1,174.80 Cr | 368.00 Cr | 362.90 Cr | 356.10 Cr | 0.00 Cr | -24.90 Cr | 686.8000 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | 461.5000 Cr | -19.2000 Cr | -392.4000 Cr | 425.1000 Cr | -110.7000 Cr | 283.8000 Cr | -36.4000 Cr | 562.4000 Cr | -6.3000 Cr | -384.6000 Cr | 68.7000 Cr |
| 2023-12-31 | 230.4000 Cr | 37.5000 Cr | -878.3000 Cr | 196.1000 Cr | -610.4000 Cr | 406.5000 Cr | -34.3000 Cr | 602.9000 Cr | -8.3000 Cr | -868.3000 Cr | -255.8000 Cr |
| 2022-12-31 | 398.7000 Cr | 650.9000 Cr | -1,582.7000 Cr | 376.5000 Cr | -533.1000 Cr | 1,004.9000 Cr | -22.2000 Cr | 864.3000 Cr | -8.0000 Cr | -1,573.0000 Cr | -31.4000 Cr |
| 2021-12-31 | 558.8000 Cr | 630.8000 Cr | -849.0000 Cr | 535.8000 Cr | 340.6000 Cr | 1,538.0000 Cr | -23.0000 Cr | 1,257.6000 Cr | -6.6000 Cr | -840.6000 Cr | -33.6000 Cr |
| 2020-12-31 | 611.1000 Cr | 276.4000 Cr | -810.0000 Cr | 569.7000 Cr | 77.5000 Cr | 1,197.4000 Cr | -41.4000 Cr | 677.2000 Cr | -4.6000 Cr | -803.8000 Cr | -22.2000 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 475.40 Cr | 290.90 Cr | 184.50 Cr | 0.3881 | 125.10 Cr | 76.00 Cr | 33.00 | 111.80 Cr | 0.1599 |
| 2025-06-30 | 406.30 Cr | 208.70 Cr | 197.60 Cr | 0.4863 | 152.70 Cr | 69.50 Cr | 30.18 | 95.15 Cr | 0.1711 |
| 2025-03-31 | 471.10 Cr | 224.60 Cr | 246.50 Cr | 0.5232 | 197.15 Cr | 94.50 Cr | 41.04 | 133.40 Cr | 0.2006 |
| 2024-12-31 | 514.90 Cr | 264.70 Cr | 250.20 Cr | 0.4859 | 175.70 Cr | 91.30 Cr | 39.64 | 116.33 Cr | 0.1773 |
| 2024-09-30 | 524.00 Cr | 260.00 Cr | 264.00 Cr | 0.5038 | 207.30 Cr | 82.20 Cr | 35.69 | 118.50 Cr | 0.1569 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 295.10 Cr | 17.80 Cr | 312.90 Cr | 161.60 Cr | 271.70 Cr | 780.30 Cr | 324.00 Cr | 1,238.90 Cr | 456.80 Cr |
| 2025-03-31 | 0.00 Cr | 0.00 Cr | 283.80 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -860.60 Cr |
| 2024-12-31 | 283.80 Cr | 56.20 Cr | 340.00 Cr | 276.50 Cr | 499.80 Cr | 1,126.80 Cr | 329.30 Cr | 1,611.80 Cr | 751.20 Cr |
| 2024-09-30 | 0.00 Cr | 0.00 Cr | 248.20 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -684.60 Cr |
| 2024-06-30 | 248.20 Cr | 14.70 Cr | 262.90 Cr | 180.00 Cr | 356.20 Cr | 876.80 Cr | 329.90 Cr | 1,360.30 Cr | 675.70 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 69.50 Cr | 145.50 Cr | -3.55 Cr | -136.30 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -7.20 Cr | 138.30 Cr |
| 2025-03-31 | 94.50 Cr | 145.50 Cr | -3.55 Cr | -136.30 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -7.20 Cr | 138.30 Cr |
| 2024-12-31 | 91.30 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 283.80 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 82.20 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | 103.20 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| No split history data available. | ||
Similar Stocks: Drug Manufacturers - General
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Cipla Limited | CIPLA | ₹1,520.10 | ₹1,227,883,769,553.00 | ₹813,485.00 |
| Abbott India Limited | ABBOTINDIA | ₹28,925.00 | ₹614,636,060,350.00 | ₹8,644.00 |
| GlaxoSmithKline Pharmaceuticals Limited | GLAXO | ₹2,545.00 | ₹431,138,356,530.00 | ₹159,008.00 |
| Gland Pharma Limited | GLAND | ₹1,750.00 | ₹288,323,740,250.00 | ₹106,396.00 |
| Pfizer Limited | PFIZER | ₹4,995.00 | ₹228,509,921,340.00 | ₹15,873.00 |
| Sanofi Consumer Healthcare India Ltd. | SANOFICONR | ₹4,670.00 | ₹107,553,004,740.00 | ₹1,669.00 |
| Sanofi India Limited | SANOFI | ₹4,337.30 | ₹99,890,716,801.00 | ₹17,076.00 |
| Marksans Pharma Limited | MARKSANS | ₹183.80 | ₹83,291,496,515.00 | ₹682,776.00 |
| Senores Pharmaceuticals Ltd. | SENORES | ₹778.00 | ₹35,829,691,464.00 | ₹222,463.00 |
Key Executives
Gender: male
Year Born: 1975
Gender: male
Year Born:
Gender: male
Year Born:
Gender: male
Year Born: 1962
Gender: male
Year Born: 1955
Gender: male
Year Born:
Gender: male
Year Born:
Gender: female
Year Born:
Gender: male
Year Born:
Gender: female
Year Born:
FAQs about Sanofi India Limited
The CEO is Rachid Ayari.
The current price is ₹4,337.30.
The range is ₹4305-6717.
The market capitalization is ₹9,989.07 crores.
The dividend yield is 4.43%.
The P/E ratio is 30.15.
The company operates in the Healthcare sector.
Overview of Sanofi India Limited (ISIN: INE058A01010) is a leading Drug Manufacturers - General in India. With a market capitalization of ₹9,989.07 crores and an average daily volume of 16,299 shares, it operates in the Drug Manufacturers - General. The company last declared a dividend of ₹192.